A new study from University of Kentucky Markey Cancer researchers demonstrates a combination of two drugs may be useful to treat ovarian cancers that are resistant to paclitaxel.
Sep 29, 2021
0
24
Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results ...
Dec 17, 2019
0
1
One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, ...
Dec 12, 2019
0
6
(HealthDay)—Taxane plus platinum regimens may be a reasonable alternative to doxorubicin plus cisplatin as postoperative adjuvant chemotherapy for endometrial cancer that carries a high risk for progression, according to ...
Mar 27, 2019
0
1
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
(HealthDay)—Exposure to paclitaxel in drug-coated balloons used in procedures for the treatment of symptomatic femoropopliteal peripheral arterial disease is not associated with mortality, according to a study published ...
Jan 28, 2019
0
2
Researchers in Brazil have discovered a new effect of a drug widely used as a chemotherapeutic agent and offered to patients free of charge by SUS, the national health service.
Oct 25, 2018
0
2
(HealthDay)—For patients with previously treated advanced gastric cancer or gastro-esophageal junction cancer, pembrolizumab does not result in a significant improvement in overall survival compared with paclitaxel, according ...
Jul 3, 2018
0
3
European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be ...
Sep 4, 2017
0
1
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination ...
Apr 18, 2016
0
15
